VTX-1218, a monoclonal antibody (mAb), exhibits an affinity for VSIG4 (V-set and immunoglobulin domain containing 4), a type-I receptor belonging to the B7-like family. This receptor is notably abundant on tumor-associated macrophages and dendritic cells across various tumor types. VTX-1218 demonstrates the capability to repolarize macrophages into a pro-inflammatory state, thereby triggering T-cell activation and fostering the recruitment of other immune cells. This orchestrated response culminates in a potent antitumor effect. In contrast to VTX-0811, VTX-1218 modulates disparate molecular pathways governing macrophage biology and showcases distinct expression profiles across various immune cell subsets. Furthermore, it exhibits elevated target expression in numerous tumor types.